Acute Migraine Treatment Market Overview, Analysis And Demand By 2034
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Estimated Market Size and CAGR of the Acute Migraine Treatment Market for the Period 2025–2029?
The acute migraine treatment market size has grown rapidly in recent years. It will grow from $2.6 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to the increasing prevalence of migraine, growth of specialty clinics, increasing funding for migraine research, growth in clinical trials, and increasing use of preventive medications.
The acute migraine treatment market size is expected to see rapid growth in the next few years. It will grow to " $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to the increasing prevalence of migraine, growing investment in migraine research, rising demand for non-invasive treatment options, rising demand for quick-acting relief options, and growing emphasis on patient-centric drug development. Major trends in the forecast period include technological advancements, the adoption of neuromodulation devices, personalized medicine, telemedicine, and diagnostic tools.
Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18208&type=smp
Which Primary Drivers Are Expected to Shape the Future of the Acute Migraine Treatment Market?
The surging work pressure is expected to propel the growth of the acute migraine treatment market going forward. Work pressure refers to the mental, emotional, and physical strain experienced by employees due to the demands and challenges of their job responsibilities. Factors leading to a surge in work pressure include tight deadlines, a lack of resources and support, poor work-life balance, unclear roles and responsibilities, interpersonal conflicts, and organizational changes. Acute migraine treatment for surging work pressure involves managing the symptoms of migraines that may be triggered or exacerbated by high-stress situations, such as a demanding work environment. For instance, in October 2022, according to the American Psychological Association, a US-based association of psychologists, workplace stress continues to be a significant issue, with 77% of employees reporting work-related stress in the past month. Additionally, 57% noted experiencing negative effects, such as emotional exhaustion (31%), which are often linked to workplace burnout. Therefore, the surging work pressure is driving the acute migraine treatment market.
Which Segments Are Likely to Shape the Future Outlook of the Acute Migraine Treatment Market?
The acute migraine treatmentmarket covered in this report is segmented –
1) By Drug Type: Triptans; Calcitonin Gene-Related Peptide Antagonist; Nonsteroidal Anti-Inflammatory Drugs; Beta-Adrenergic; Ergot Alkaloids; Other Drug Types
2) By Route Of Administration: Oral; Injection; Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; E-Commerce
Subsegments:
1) By Triptans: Sumatriptan; Rizatriptan; Zolmitriptan; Eletriptan
2) By Calcitonin Gene-Related Peptide (CGRP) Antagonists: Erenumab; Fremanezumab; Galcanezumab
3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Diclofenac
4) By Beta-Adrenergic: Propranolol; Metoprolol; Atenolol
5) By Ergot Alkaloids: Ergotamine; Dihydroergotamine
6) By Other Drug Types: Antiemetic Drugs; Antidepressants; Corticosteroids
Which Future-Ready Trends Are Expected to Influence the Acute Migraine Treatment Market?
Major companies operating in the acute migraine treatment market are focused on developing innovative products, such as migraine nasal sprays, to enhance the efficacy and convenience of migraine relief. Migraine nasal sprays are a form of acute migraine treatment that delivers medication through the nasal passages. This route of administration can be advantageous because it allows for rapid absorption of the medication, which can provide faster relief compared to oral medications. For instance, in March 2023, Pfizer Inc., a US-based biotechnology company, launched ZAVZPRET (zavegepant) Migraine Nasal Spray, approved by the Food and Drug Administration (FDA), a US-based federal agency. This innovative nasal spray leverages the efficacy of zavegepant, a CGRP receptor antagonist, which blocks the calcitonin gene-related peptide (CGRP) pathway to provide rapid and targeted relief from migraine attacks. The unique features of ZAVZPRET include its fast-acting formulation, which delivers relief within 15 minutes, making it a convenient option for individuals seeking quick alleviation from severe migraine symptoms.
Which Firms Represent the Competitive Benchmark Within the Acute Migraine Treatment Market?
Major companies operating in the acute migraine treatment market are Pfizer Inc., Johnson And Johnson, Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Viatris Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Endo International plc, Supernus Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Upsher-Smith Laboratories LLC, BioDelivery Sciences International Inc., Axsome Therapeutics Inc., Impel NeuroPharma Inc., Currax Pharmaceuticals LLC, Satsuma Pharmaceuticals Inc.
Get the detailed acute migraine treatment market report today
https://www.thebusinessresearchcompany.com/report/acute-migraine-treatment-global-market-report
Which Regions Are Driving the Highest Demand in the Acute Migraine Treatment Market?
North America was the largest region in the acute migraine treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment